Aminolevulinic acid ( DrugBank: Aminolevulinic acid )

4 diseases

ID	Disease name (Link within this page)	Number of trials
34	Neurofibromatosis	2
96	Crohn disease	1
254	Porphyria	2
286	Hereditary sideroblastic anemia	2

34. Neurofibromatosis

Clinical trials : 137 / Drugs : 213 - (DrugBank : 76) / Drug target genes : 87 - Drug target pathways : 200

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02728388 (ClinicalTrials.gov)	August 2016	25/3/2016	Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II	Topical Photodynamic Therapy (PDT) With Levulan® Kerastick® for Benign Dermal Neurofibromas Phase II	NEUROFIBROMATOSIS 1	Drug: aminolevulinic acid	Harry T Whelan, MD	NULL	Recruiting	14 Years	30 Years	All	30	Phase 2	United States
2	NCT01682811 (ClinicalTrials.gov)	March 12, 2012	5/9/2012	Phase I Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1)	Photodynamic Therapy for Benign Dermal Neurofibromas Using Levulan Kerastick For Topical Solution, Plus Illumination With Red Light	Neurofibromatoses	Drug: Part 1 Levulan injection;Drug: Part 1 Levulan surface application;Drug: Part 1 Levulan surface application twice;Drug: Part 1 Levulan surface application twice with microneedling;Drug: Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 1;Drug: Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 2;Drug: Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 3	Harry T Whelan, MD	NULL	Completed	18 Years	90 Years	All	20	Phase 1	United States

96. Crohn disease

Clinical trials : 2,400 / Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04164849 (ClinicalTrials.gov)	November 22, 2019	8/11/2019	Extracorporeal Photopheresis of Patients With Crohn's Disease Using 5-aminolevulinic Acid	Extracorporeal Photopheresis of Patients With Crohn's Disease Using 5-aminolevulinic Acid	Crohn Disease	Drug: 5-aminolevulinic acid;Procedure: Blue light photopheresis;Procedure: Transfusion;Procedure: Continuous Mononuclear Cell Collection (CMNC);Procedure: Red light photopheresis	University Hospital, Akershus	Oslo University Hospital	Recruiting	18 Years	N/A	All	10	Phase 1/Phase 2	Norway

254. Porphyria

Clinical trials : 70 / Drugs : 54 - (DrugBank : 19) / Drug target genes : 19 - Drug target pathways : 35

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04923516 (ClinicalTrials.gov)	June 2021	8/6/2021	Prevalence of Acute Hepatic Porphyria	Prevalence of Acute Hepatic Porphyria in Population With Suggestive Clinical Picture	Acute Hepatic Porphyria	Other: Dosage of Delta-aminolevulinic acid and Porphobilinogen	Association pour la Recherche en Medecine Interne	NULL	Not yet recruiting	18 Years	60 Years	All	500		NULL
2	NCT01550705 (ClinicalTrials.gov)	March 2012	5/3/2012	Effect of Isoniazid on Protoporphyrin Levels in Erythropoietic Protoporphyria	Quantification of the Effects of Isoniazid Treatment on Erythrocyte and Plasma Protoporphyrin IX Concentration and Plasma Aminolevulinic Acid in Patients With Erythropoietic Protoporphyria	Erythropoietic Protoporphyria (EPP);X Linked Erythropoietic Protoporphyria	Drug: Isoniazid	University of Utah	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);Icahn School of Medicine at Mount Sinai;University of Alabama at Birmingham;University of California, San Francisco;University of Texas	Terminated	18 Years	N/A	All	11	N/A	United States

286. Hereditary sideroblastic anemia

Clinical trials : 7 / Drugs : 23 - (DrugBank : 10) / Drug target genes : 8 - Drug target pathways : 42

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000023490	2016/08/20	05/08/2016	The Safety and Efficacy of 5-Aminolevulinic Acid (ALA) Therapy for Sideroblastic Anemia		Sideroblastic anemia (congenital and acquired)	Food supplement containing 150 mg of ALA phosphate was given per day for 24 weeks. For the evaluation of efficacy and safety, medical examinations as well as urine and blood tests will be performed prior to administration of ALA, then at 2 and 4 weeks, and thereafter every month (up to 12 months).	Department of Hematolgy and Rheumatology, Tohoku University Graduate School of Medicine	NULL	Complete: follow-up complete	20years-old	80years-old	Male and Female	5	Not applicable	Japan
2	JPRN-UMIN000021407	2016/03/15	15/03/2016	A study of efficacy and safety of 5-aminolevulinic acid phosphate in patients with sideroblastic anemia	A study of efficacy and safety of 5-aminolevulinic acid phosphate in patients with sideroblastic anemia - Efficacy and safety of 5-ALA phosphate in patients with sideroblastic anemia	sideroblastic anemia	Orally intake a 150 mg 5-aminolevulinic acid phosphate capsule once a day for up to 24 weeks.	Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University	SBI Pharmaceuticals Co., Ltd	Complete: follow-up continuing	20years-old	80years-old	Male and Female	5	Not applicable	Japan